Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
15 Dec 2023, 18:56:13 UTC
Prior SEC filing
12 Apr 2022
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
ADVANCE/NEWHOUSE PROGRAMMING PARTNERSHIP, By: /s/ Oren Klein, Its: Chief Financial Officer

Key filing fact

ADVANCE/NEWHOUSE PROGRAMMING PARTNERSHIP filed Form 4 for Warner Bros. Discovery, Inc. (WBD) on 15 Dec 2023.

Key facts

  • This page summarizes ADVANCE/NEWHOUSE PROGRAMMING PARTNERSHIP's Form 4 filing for Warner Bros. Discovery, Inc. (WBD).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 15 Dec 2023, 18:56.

Change

  • Previous filing in this sequence was filed on 12 Apr 2022.
  • Current net transaction value: -$124,900,000.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

WBD transaction

Series A common stock, par value $0.01 per share

Sale

Transaction value
$124,900,000
Shares
-10,000,000
Change %
-5.2%
Price
$12.49
Shares after
184,023,290
Date
14 Dec 2023
Ownership
Direct
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

SEC remarks

Each of Newhouse Broadcasting Corporation and Advance Publications, Inc. may be deemed to beneficially own shares of Series A common stock, par value $0.01 per share of Warner Bros. Discovery, Inc. held by Advance/Newhouse Programming Partnership, a New York Partnership ("ANP") due to their control of ANP.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .